Tech News Point

Delveinsight Business Research LLP

DelveInsight’s “Behçet’s Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Behçet’s Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Behçet’s Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Behçet’s Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Behçet’s Disease: An Overview

Behçet’s syndrome also known as Bycet disease is a rare chronic, relapsing, and debilitating inflammatory multisystem disease of unknown etiology characterized by ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes. Typically, painful canker sores on the mouth’s mucous membranes are Behçet’s syndrome’s first sign (aphthous stomatitis). The eyes may potentially be impacted by Behçet’s syndrome. Inflammation of the anterior chamber and the posterior uveitis are two symptoms that can occur (anterior uveitis or iridocyclitis). It is also possible for the iris to become inflamed and experience pain, tearing, and pus buildup (hypopyon iritis).

Due to the absence of any pathognomic test findings, Behcet’s must be diagnosed clinically, which can be challenging. Leukocytosis, elevated inflammatory marker levels, and anemia of chronic disease are examples of common, non-specific laboratory results. Imaging studies must focus on the affected organ and may include X-rays, arthrocentesis to evaluate arthritis, CT scans to evaluate for bleeding, thrombosis, and ischemia, angiography to look for aneurysms and lumbar punctures to assess meningitis. Imaging studies must also be directed at the affected organ.

The goal of treatment is to prevent organ damage. Based on organ involvement, severity, and prognostic variables, the treatment plan is chosen. If severe vascular involvement is unresponsive to medical management, surgical measures may be necessary. Fistulas, intestinal stenosis, perforations, pulmonary artery aneurysms, glaucoma, cataracts, and CNS aneurysms are also treated surgically.

Behçet’s Disease Market Key Facts

• According to Orphanet (2020), Behçet disease is a rare, chronic, relapsing, multisystemic vasculitis characterized by mucocutaneous lesions, as well as articular, vascular, ocular, and central nervous system manifestations. It is most often reported in populations along the Silk Road. The total prevalence of Behcet’s disease in Japan was 1 per 10,000 cases.

• The total Behcet’s syndrome diagnosed patient population in the 7MM countries was approximately 69,000 cases in 2021.

• Among the EU4 countries, Italy had the highest Behcet’s syndrome diagnosed patient population, with over 6,000 cases, followed by France in 2021. On the other hand, Germany had the lowest diagnosed prevalent patient population of Behcet’s syndrome, with ~1,000 cases in 2021.

• As per Hammam et al (2021) study, the prevalence of BD in the US is increasing and patients are predominantly female as compared to males (3.8:1). Approximately, 79.3% were female predilection.

• As per Killan and Sawalha’s (2017) study, Behçet’s disease is heterogeneous with clinical variability across ethnicities and geographic locations. The prevalence of Behcet’s disease in the US was 5.2 per 100,000 cases.

Behçet’s Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Behçet’s Disease pipeline therapies. It also thoroughly assesses the Behçet’s Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Behçet’s Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Behçet’s Disease Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Behçet’s Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Behçet’s Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Behçet’s Disease Epidemiology, Segmented as –

• Total Prevalent Cases of Behcet’s Syndrome in the 7MM (2019–2032)

• Total Diagnosed Cases of Behcet’s Syndrome in the 7MM (2019–2032)

• Total Treated Cases of Behcet’s Syndrome in the 7MM (2019–2032)

• Total Gender-specific Cases of Behcet’s Syndrome in the 7MM (2019–2032)

Behçet’s Disease Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Behçet’s Disease market or expected to be launched during the study period. The analysis covers the Behçet’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Behçet’s Disease drugs based on their sale and market share.

The report also covers the Behçet’s Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Behçet’s Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Behçet’s Disease Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/behcets-disease-market

Behçet’s Disease Therapeutics Analysis

It has no cure and is associated with significant morbidity and mortality. Poor prognosis and higher mortality are related to male sex and younger age of onset. Besides increased mortality, it is associated with several potential lifelong complications, most of which are a result of ocular or neurologic involvement. Such as patients with hypopyon-related uveitis and retinal involvement are at a high risk of blindness.

Treatment is aimed at preventing organ damage. The treatment strategy is decided based on organ involvement, severity, and prognostic factors. In 2019, Apremilast was approved for the treatment of oral ulcers in Behcet’s disease. Additionally, Surgical interventions may be indicated in extensive vascular involvement refractory to medical management. Surgery is also used to manage fistulas, intestinal stenosis, perforation, pulmonary artery aneurysms, glaucoma, cataracts, and CNS aneurysms.

Besides corticosteroids, these patients need other anti-inflammatory or immunosuppressive agents. Treatment for Behcet’s disease is symptomatic and supportive. Medication may be prescribed to reduce inflammation and/or regulate the immune system. Immunosuppressive therapy may be considered.

Several major pharma and biotech companies developing therapies for Behçet disease. Currently, Novartis is leading the therapeutics market with its Behçet disease drug candidates in the most advanced stage of clinical development.

Behçet’s Disease Companies Actively Working in the Therapeutics Market Include

• AbbVie

• Eisai Co. Ltd

• Nobel Pharmaceuticals

• Ainos Inc.

• Amgen

• Ganzhou Hemay Pharmaceutical Co. Ltd

• Janssen Korea Ltd

• Mitsubishi Tanabe Pharma Corporation

• Bristol-Myers Squibb

• Hoffmann- La Roche

• Novartis Pharmaceuticals

• Abbott

• Sanguine Biosciences

• GlaxoSmithKline

• IItoo Pharma

And Many Others

Emerging and Marketed Behçet’s Disease Therapies Covered in the Report Include:

• Canakinumab: Novartis

• OTEZLA: Amgen

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/behcets-disease-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Behçet’s Disease Competitive Intelligence Analysis

4. Behçet’s Disease Market Overview at a Glance

5. Behçet’s Disease Disease Background and Overview

6. Behçet’s Disease Patient Journey

7. Behçet’s Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Behçet’s Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Behçet’s Disease Unmet Needs

10. Key Endpoints of Behçet’s Disease Treatment

11. Behçet’s Disease Marketed Therapies

12. Behçet’s Disease Emerging Drugs and Latest Therapeutic Advances

13. Behçet’s Disease Seven Major Market Analysis

14. Attribute Analysis

15. Behçet’s Disease Market Outlook (In US, EU5, and Japan)

16. Behçet’s Disease Companies Active in the Market

17. Behçet’s Disease Access and Reimbursement Overview

18. KOL Views on the Behçet’s Disease Market

19. Behçet’s Disease Market Drivers

20. Behçet’s Disease Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/behcets-disease-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Treatment-Resistant Depression (TRD) Market

“Treatment-Resistant Depression Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Treatment-Resistant Depression market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Treatment-Resistant Depression market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research